Affiliation:
1. Laboratory of Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Chungbuk, Republic of Korea
Abstract
Cholangiocarcinoma (CCA) is a malignant biliary tract tumor with a high mortality rate and refractoriness to chemotherapy. Gemcitabine is an anti-cancer chemotherapeutic agent used for CCA, but the efficacy of gemcitabine in CCA treatment is limited, due to the acquisition of chemoresistance. The present study evaluated the chemosensitizing effects of Amurensin G (AMG), a natural sirtuin-1 inhibitor derived from Vitis amurensis, in the SNU-478 CCA cells. Treatment with AMG decreased the SNU-478 cell viability and the colony formation ability. Annexin V/ Propidium iodide staining showed that the AMG increased apoptotic death. In addition, AMG downregulated anti-apoptotic Bcl-2 expression, while upregulating pro-apoptotic cleaved caspase-3 expression. Treatment with AMG decreased the migratory ability of the cells in a wound healing assay and transwell migration assay. It was observed that AMG decreased the gemcitabine-induced increase in CD44highCD24highCD133high cell populations, and the expression of the Sox-2 protein was decreased by AMG treatment. Co-treatment of AMG with gemcitabine significantly enhanced the production of reactive oxygen species, as observed through mitochondrial superoxide staining, which might be associated with the downregulation of the Sirt1/Nrf2 pathway by AMG. These results indicate that AMG enhances the chemotherapeutic ability of gemcitabine by downregulating cancer stem-like properties in CCA cells. Hence, a combination therapy of AMG with gemcitabine may be an attractive therapeutic strategy for cholangiocarcinoma.
Funder
National Research Foundation (NRF) of Korea
Ministry of Science and ICT
Ministry of Education
Subject
Food Science,Nutrition and Dietetics
Reference36 articles.
1. Cholangiocarcinoma 2020: The next horizon in mechanisms and management;Banales;Nat. Rev. Gastroenterol. Hepatol.,2020
2. Wu, H.J., and Chu, P.Y. (2019). Role of cancer stem cells in cholangiocarcinoma and therapeutic implications. Int. J. Mol. Sci., 20.
3. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N. Engl. J. Med.,2010
4. Clinical treatment of cholangiocarcinoma: An updated comprehensive review;Elvevi;Ann. Hepatol.,2022
5. Pandit, B., and Royzen, M. (2022). Recent development of prodrugs of gemcitabine. Genes, 13.